Piramal Pharma Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For PPLPHARMA, that strike is ₹160. Spot at ₹160.15 is 6.01% above max pain — possible downward gravitational pull into expiry.
Max Pain Level
The maximum pain strike for Piramal Pharma Limited (PPLPHARMA) is ₹160, where option writers experience the least aggregate loss at expiry. Max pain acts as a magnet in the final days, as dealers adjust to minimize payouts on outstanding contracts.
Spot vs Max Pain Gap
The spot price at ₹169.61 sits 6.01% above the ₹160 pain point, creating downward pressure as the market may drift toward reduced assignment risk. This gap suggests underlying imbalance, with incentive for price alignment before expiry.
Shift Signal
The max pain level remains unchanged from yesterday, indicating stable writer positioning around ₹160. Persistent stability reflects consistent open interest concentration in near-term strikes.
Expiry Bias
With zero days to expiry, any drift toward ₹160 would reflect last-minute dealer hedging rather than sustained trend. Such dynamics grow stronger inside five days as gamma effects amplify price attraction.
Trader Note
With expiry at hand, premium decay strategies are viable only now, capitalizing on time erosion in short-dated options.
Data as of 2026-04-28